NORWALK, CT (January 18, 2005) – PharmaDiscovery 2005, produced by Elsevier’s Drug Discovery Today and Reed Exhibitions, announced a leading scientific line-up of speakers from the drug discovery community, at PharmaDiscovery on May 10-12, 2005, at the Washington, DC Convention Center.
PharmaDiscovery, described as “by scientists for scientists,” combines scientific insight with drug discovery technology, organizers said.
“We are privileged to have so many elite members of the drug discovery community who have accepted our invitation to speak. They support a purely scientific event that will force debate on the critical issues preventing the closure of the drug discovery productivity gap,” Kevin Richards, industry vice president, Reed Exhibitions, said.
The conference program was developed to encourage scientific debate and audience participation. Presentations, led by scientists, will focus on objectives and tackle key issues within each discipline, organizers said.
The conference will include daily sum-up sessions to relay the key points and conclusions from each session back to the entire audience, facilitating the exchange of information between chemists and biologists, and helping to break down drug discovery silos.
The sessions will focus on the convergence of scientific insight and drug discovery technologies. They will include:
• Pharmacological Models for Human Diseases
• Pharmacological Models for CNS Diseases
• Target Assessment
• IT Infrastructure as a Source of Value Creation for the Drug Discovery Process
• In Silico Drug Discovery
• Chemistry Driven Drug Discovery: Proof of Concept Ligands
• Evaluating Success in Drug Discovery: Where We Are & Where We Go Next
• In Vivo Models in Drug Development
• Pre-Clinical Safety & Drug Development
• Data Integration
• Efficacy Biomarkers in Early Clinical Development: Stop/Go Decision Makers or Risk Management Tools?
• Chemistry Driven Drug Discovery: Breakthrough Medicines
• Focused sessions on Biomarker Technologies, GPCRs, Kinases, Ion Channels & Proteases
Speakers will include:
• Dr. Dimitris Agrafiotis, Senior Research Fellow & Team Leader, Molecular Design & Informatics, Johnson & Johnson
• Dr. Martyn Banks, Director of Drug Discovery, Bristol-Myers Squibb
• Dr. John Brown, Global Head of Translational Medicine & Technology, GlaxoSmithKline
• Dr. Bruce Car, Executive Director, Discovery Toxicology, Bristol-Myers Squibb
• Dr. Wendy Cornell, Director of Molecular Systems, Merck
• Dr. Carlos Garcia Escheverria, Novartis Institutes for Biomedical Research
• Dr. Frank Gonzalez, Chief of Lab of Metabolism, Centre for Cancer Research, National Cancer Institute, NIH
• Dr. Val Goodfellow, Associate Director, Neurocrine Biosciences
• Dr. Peter Haddock, Ion Channel Pharmacology Group Leader, Pfizer Ann Arbor Labs
• Dr. Kenneth Jacobson, Molecular Recognition Section Chief, Lab of Bioorganic Chemistry, NIDDK, NIH
• Dr. Ken Korzekwa, Director, Pre-Clinical Drug Metabolism, Merck
• Dr. Peter Lord, Director of Mechanistic Toxicology, Johnson & Johnson
• Dr. Mike Luther, VP Discovery Research, GlaxoSmithKline
• Professor Graeme Milligan, Institute of Biomedical & Life Sciences, Univ of Glasgow
• Dr. Mark Murcko, Chief Technology Officer, Vertex Pharmaceuticals
• Professor Steve Naylor, Computational Systems Biology Initiative, Massachusetts Institute of Technology
• Professor Patrick Nef, Head Molecular Neurobiology, F Hoffmann-La Roche Ltd
• Dr. Eric Neumann, Global Head of Knowledge Management, Aventis Drug Innovation & Appproval
• Professor Bernhard Palsson, Department of Bioengineering, University of California, San Diego
• Dr. Anthony G Quinn, VP Discovery Medicine, Roche, Palo Alto
• Professor Andy Randall, Director of Neurophysiology Neurology & GI CEDD, GlaxoSmithKline
• Dr. Jack Reynolds, Global Head of Safety Sciences, Pfizer R&D
• Dr. Edward A. Sausville, Greenebaum Cancer Center, University of Maryland, Baltimore
• Professor Thue Schwartz, Chief Scientific Officer, 7TM Pharma A/S
• Dr. Ronald Shymko, Head of Scientific Computing, Novo Nordisk
• Dr. James Stevens, Research Fellow, Toxicology & Drug Disposition, Lilly Research Labs
• Dr. James Summers, Division VP, Advanced Technology, Abbott Labs
• Dr. Hans Winkler, Senior Director of Functional Genomics, Johnson & Johnson
• Dr. Richard Woychik, Director, Jackson Lab
Keynote speakers are:
• Dr. Janet Woodcock, Acting Deputy Commissioner for Operations, Center for Drug Development & Research, US Food & Drug Administration (FDA), on May 12. She will speak on the FDA perspective on challenges and opportunities on the critical path to new medicinal products.
• Dr. Robert R. Ruffolo Jr, President, R&D, Wyeth Pharmaceuticals, Senior VP, Wyeth Corp. on May 11 will speak on Maximizing The Tools Of Drug Discovery To Improve Productivity.
PharmaDiscovery is expected to attract members of the academic and pharmaceutical scientific R&D communities, regulatory authorities and developers and suppliers of critical technologies.
An exhibit hall will feature exhibitors in categories such as automation integration, chemistry-related products, contract research, sample preparation, microarray products, custom databases, lab equipment, proteomics, screening and assay tools.
Exhibitors will include Apple Computer Inc, CambridgeSoft Corp., CEM Corp., ChromaVision Medical Systems Inc., Drug Discovery Today, EMD Biosciences Inc., Fujitsu America, In Vitro Technologies, Key Organics Ltd., MDL Information Systems Inc., Metabolon, Molecular Devices Corp., Nature Publishing Group, NeuroScience Associates, Pharmacore Inc., RBI US Life Science Group, sciencejobs.com, SelectScience and others.
Organizers: Elsevier produces scientific, technical and medical products including the highly regarded journals Drug Discovery Today, Cell, Tetrahedron, Lancet, and the scientific information platform, ScienceDirect. Other endorsing Reed Elsevier groups focused on drug discovery solutions include: Reed Business Information Science Group (Drug Discovery & Development Magazine, Bioscience Technology, Scientific Computing & Instrumentation Magazine, Genomics & Proteomics, Laboratory Equipment and R&D Magazine), MDL, and ScienceJobs.com/New Scientist.
The event will be produced and managed by Reed Exhibitions, a major organizer of business-to-business events. Reed events are held in 35 countries and are organized by 30 international offices serving 49 industries.
(Editor’s Note: Pharmaceutical Processing magazine and this Website are owned and operated by Reed Business Information).